- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy in the treatment of uterine serous carcinoma
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 16, Issue 2, Pages 97-99
Publisher
Future Medicine Ltd
Online
2015-01-23
DOI
10.2217/pgs.14.176
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
- (2014) C L Schwab et al. BRITISH JOURNAL OF CANCER
- Dual HER2 Targeting Impedes Growth of HER2 Gene-Amplified Uterine Serous Carcinoma Xenografts
- (2014) J. W. Groeneweg et al. CLINICAL CANCER RESEARCH
- Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo
- (2014) Carlton L. Schwab et al. GYNECOLOGIC ONCOLOGY
- Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
- (2014) Salvatore Lopez et al. GYNECOLOGIC ONCOLOGY
- T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
- (2014) Diana P. English et al. Cancer Medicine
- Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)
- (2013) Diana P. English et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor
- (2013) Diana P. English et al. GYNECOLOGIC ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
- (2013) Natalia Buza et al. MODERN PATHOLOGY
- Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
- (2013) S. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
- (2011) P Todeschini et al. BRITISH JOURNAL OF CANCER
- Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer
- (2011) Karim S El-Sahwi et al. Expert Review of Anticancer Therapy
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
- (2009) Gini F. Fleming et al. GYNECOLOGIC ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More